This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FIXX Homology Medicines (FIXX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Homology Medicines Stock (NASDAQ:FIXX) 30 days 90 days 365 days Advanced Chart Get Homology Medicines alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.33▼$16.8252-Week Range N/AVolume22,300 shsAverage Volume390,307 shsMarket Capitalization$978.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts. Read More Homology Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreFIXX MarketRank™: Homology Medicines scored higher than 11% of companies evaluated by MarketBeat, and ranked 886th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Homology Medicines. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Homology Medicines are expected to grow in the coming year, from ($0.75) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Homology Medicines is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Homology Medicines is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for FIXX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHomology Medicines does not currently pay a dividend.Dividend GrowthHomology Medicines does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.33 Short InterestThere is no current short interest data available for FIXX. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for FIXX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Homology Medicines insiders have not sold or bought any company stock.Percentage Held by Insiders16.10% of the stock of Homology Medicines is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.32% of the stock of Homology Medicines is held by institutions.Read more about Homology Medicines' insider trading history. Receive FIXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FIXX Stock News HeadlinesWhat Western medicine can learn from the ancient history of psychedelicsSeptember 13, 2024 | bbc.comBOfficials in North Korea seek medicine for Kim Jong Un's health problems related to obesity, Seoul saysAugust 2, 2024 | nbcnews.comMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also brings new risks for retirement savers. Traditional 401(k)s and IRAs may leave investors more exposed than they realize. That’s why a Trump-backed IRS strategy is gaining attention. It allows everyday Americans to reposition their retirement savings into real assets like gold and silver — offering both protection and potential upside. A new 2025 Wealth Protection Guide explains exactly how it works.September 10 at 2:00 AM | American Alternative (Ad)Homology Medicines, Inc.: Homology Medicines Declares Distribution to Common StockholdersMarch 24, 2024 | finanznachrichten.deFIXX Homology Medicines, Inc.March 23, 2024 | seekingalpha.comHomology Medicines Declares Distribution to Common StockholdersMarch 18, 2024 | finance.yahoo.comHOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXFebruary 27, 2024 | businesswire.comHomology Medicines Inc (FIXX)February 2, 2024 | investing.comSee More Headlines FIXX Stock Analysis - Frequently Asked Questions How were Homology Medicines' earnings last quarter? Homology Medicines, Inc. (NASDAQ:FIXX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. The firm earned $1.68 million during the quarter, compared to analysts' expectations of $0.63 million. Homology Medicines had a negative trailing twelve-month return on equity of 102.52% and a negative net margin of 4,779.31%. When did Homology Medicines' stock split? Homology Medicines shares split on Wednesday, March 20th 2024.The 2-1 split was announced on Wednesday, March 20th 2024. The newly created shares were distributed to shareholders after the market closes on Wednesday, March 20th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. When did Homology Medicines IPO? Homology Medicines (FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Homology Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Homology Medicines investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Enovix (ENVX), Luminar Technologies (LAZR), Advanced Micro Devices (AMD), Ginkgo Bioworks (DNA) and Tesla (TSLA). Company Calendar Last Earnings11/15/2021Today9/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FIXX CIK1661998 Webwww.homologymedicines.com Phone(781) 301-7277FaxN/AEmployees7Year Founded2015Profitability EPS (Trailing Twelve Months)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$112.96 million Net Margins-4,779.31% Pretax Margin-7,532.87% Return on Equity-102.52% Return on Assets-74.91% Debt Debt-to-Equity RatioN/A Current Ratio7.25 Quick Ratio7.25 Sales & Book Value Annual Sales$1.16 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.26 per share Price / BookN/AMiscellaneous Outstanding Shares58,130,000Free Float48,774,000Market Cap$978.01 million OptionableOptionable Beta-0.10 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:FIXX) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Obscure Korean War Act That Created a $5.39 Billion Passive Income StreamAn obscure Korean War law has just been enacted by the U.S. government... Allowing it to take a heavy hand ...Angel Publishing | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Homology Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Homology Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.